TY  - JOUR
AU  - Wen, Yujie
AU  - Chhabra, Anita
AU  - Ildstad, Suzanne T.
AU  - Leventhal, Joseph
PY  - 2018
DA  - 2018/11/20
TI  - Allogeneic Hematopoietic Cell Therapies to Induce Tolerance in Kidney Transplantation
JO  - OBM Transplantation
SP  - 027
VL  - 02
IS  - 04
AB  - In this review, we summarized the latest results from the interventional clinical trials on inducing clinical tolerance in the recipients of human leukocyte antigen (HLA)-matched or mismatched living donor kidney transplantation via establishment of either transient or durable donor chimerism by hematopoietic stem cell (HSC)-based cell therapies. The protocols utilized by the three medical centers in the United States are different in the donor cells composition of hematopoietic stem cells transplantation (HSCT) and its timing, and the conditioning regimen prepared for the transplantation. Tolerant recipients from the clinical trials benefited from better long-term outcome, improved quality of life and reductions in lifetime healthcare expenses compared with Standard of Care recipients on conventional immunosuppression.  Durable chimerism is indispensable to achieve immunologic tolerance to kidney transplantation and to protect against recurrence of the original renal disease in HLA-mismatched kidney transplant recipients by concomitant HSCT.
SN  - 2577-5820
UR  - https://doi.org/10.21926/obm.transplant.1804027
DO  - 10.21926/obm.transplant.1804027
ID  - Wen2018
ER  -